Free Access
Med Sci (Paris)
Volume 18, Number 10, Octobre 2002
Page(s) 975 - 981
Section M/S Revues : Articles de Synthèse
Published online 15 October 2002
  1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996; 65 : 635–92. [Google Scholar]
  2. Champoux JJ. Mechanistic aspects of type-I topoisomerases. In : Wang JC, Cozarelli NR, eds. DNA topology and its biological effects. Cold Spring Harbor, NY : Cold Spring Harbor Laboratory Press, 1990 : 217–42. [Google Scholar]
  3. Stewart L, Redinbo MR, Qiu X, et al. A model for the mechanism of human topoisomerase I. Science 1998; 279 : 1534–41. [Google Scholar]
  4. Svejstrup JQ, Christiansen K, Gromova II, et al. New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site. J Mol Biol 1991; 222 : 669–78. [Google Scholar]
  5. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49 : 5077–82. [Google Scholar]
  6. Pommier Y, Pourquier P, Urasaki Y, et al. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 1999; 2 : 307–18. [Google Scholar]
  7. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000; 7 : 39–58. [Google Scholar]
  8. Holm C, Covey JM, Kerrigan D, et al. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989; 49 : 6365–8. [Google Scholar]
  9. Shykind BM, Kim J, Stewart L, et al. Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev 1997; 11 : 397–407. [Google Scholar]
  10. Haluska P Jr, Saleem A, Rasheed Z, et al. Interaction between human topoisomerase I and a novel RING finger/arginineserine protein. Nucleic Acids Res 1999; 27 : 2538–44. [Google Scholar]
  11. Bhart AK, Olson MO, Kufe DW, et al. Identification of a nucleolin binding site in human topoisomerase I. J Biol Chem 1996; 271 : 1993–7. [Google Scholar]
  12. Rossi F, Labourier E, Forne T, et al. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 1996; 381 : 80–2. [Google Scholar]
  13. Straub T, Grue P, Uhse A, et al. The RNA-splicing factor PSF/p54 controls DNA-topoisomerase I activity by a direct interaction. J Biol Chem 1998; 273 : 26261–4. [Google Scholar]
  14. Shuman S. Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase. J Biol Chem 1994; 269 : 32678–84. [Google Scholar]
  15. Krogh BO, Shuman S. Catalytic mechanism of DNA topoisomerase IB. Mol Cell 2000; 5 : 1035–41. [Google Scholar]
  16. Cheng C, Kussie P, Pavletich N, et al. Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases. Cell 1998; 92 : 841–50. [Google Scholar]
  17. Bullock P, Champoux JJ, Botchan, M. Association of crossover points with topoisomerase I cleavage sites: a model for nonhomologous recombination. Science 1985; 230 : 954–8. [Google Scholar]
  18. Wang HP, Rogler CE. Topoisomerase I-mediated integration of hepadnavirus DNA in vitro. J Virol 1991; 65 : 2381–92. [Google Scholar]
  19. Zhu J, Schiestl RH. Topoisomerase I involvement in illegitimate recombination in Saccharomyces cerevisiae. Mol Cell Biol 1996; 16 : 1805–12. [Google Scholar]
  20. Anderson RD, Berger NA. International commission for protection against environmental mutagens and carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat Res 1994; 309 : 109–42. [Google Scholar]
  21. Lanza A, Tornaletti S, Rodolfo C, et al. Human DNA topoisomerase Imediated cleavages stimulated by ultraviolet light-induced DNA damage. J Biol Chem 1996; 271 : 6978–86. [Google Scholar]
  22. Pourquier P, Pommier Y. Topoisomerase I-mediated DNA damage. Adv Cancer Res 2001; 80 : 189–216. [Google Scholar]
  23. Pourquier P, Kohlhagen G, Ueng LM, et al. Topoisomerase I and II activity assays. In : Brown R, Böger-Brown U, eds. Cytotoxic drug resistance mechanisms. Totowa : Humana Press Inc, 1999 : 95–110. [Google Scholar]
  24. Redinbo MR, Stewart L, Kuhn P, et al. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998; 279 : 1504–13. [Google Scholar]
  25. Pourquier P, Takebayashi Y, Urasaki Y, et al. Induction of topoisomerase I cleavage complexes by 1-β-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci USA 2000; 97 : 1885–90. [Google Scholar]
  26. Subramanian D, Kraut E, Staubus A, et al. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995; 55 : 2097–103. [Google Scholar]
  27. Mao Y, Okada S, Chang LS, et al. p53 dependence of topoisomerase I recruitment in vivo. Cancer Res 2000; 60 : 4538–43. [Google Scholar]
  28. Gobert C, Bracco L, Rossi F, et al. Modulation of DNA topoisomerase I activity by p53. Biochemistry 1996; 35 : 5778–86. [Google Scholar]
  29. Smith ML, Chen IT, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994; 266 : 1376–80. [Google Scholar]
  30. Nitiss JL, Nitiss KC, Rose A, et al. Overexpression of type I topoisomerases sensitizes yeast cells to DNA damage. J Biol Chem 2001; 276 : 26708–14. [Google Scholar]
  31. Pourquier P, Kohlhagen G, Urasaki Y, et al. Induction of topoisomerase I cleavage complexes by staurosporine in apoptotic leukemia cells: could topoisomerase I act as an apoptotic endonuclease? Proc Am Assoc Cancer Res 2001; 42 : 303. [Google Scholar]
  32. Bonven BJ, Gocke E, Westergaard O. A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin. Cell 1985; 41 : 541–51. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.